Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals

Drug Profile

Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals

Alternative Names: Accu-Break Warfarin Potassium; Accu-Break-formatted anticoagulant

Latest Information Update: 22 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Accu-Break Pharmaceuticals
  • Developer Accu-Break Pharmaceuticals; Alembic
  • Class Anti-ischaemics; Anticoagulants; Coumarins
  • Mechanism of Action Vitamin K antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Thromboembolism

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Nov 2015 Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals is available for licensing in USA, World as of 19 Nov 2015. www.accubreakpharmaceuticals.com
  • 19 Nov 2015 Preregistration for Thromboembolism in USA (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top